A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0.32). Although not statistically different, results suggest IVB may be a promising combination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478135PMC
http://dx.doi.org/10.1111/bjh.13388DOI Listing

Publication Analysis

Top Keywords

hodgkin lymphoma
8
children's oncology
8
oncology group
8
phase study
4
study bortezomib
4
bortezomib combination
4
combination ifosfamide/vinorelbine
4
ifosfamide/vinorelbine paediatric
4
paediatric patients
4
patients young
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!